First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors

Background This first-in-human phase 1 study assessed the safety of TAS-114, a novel deoxyuridine triphosphatase inhibitor, combined with S-1 to determine its maximum tolerated dose (MTD) and recommended dose (RD). Methods In this dose-escalation study with a 3 + 3 design, TAS-114 and S-1 were concu...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Invest New Drugs
मुख्य लेखकों: Doi, Toshihiko, Yoh, Kiyotaka, Shitara, Kohei, Takahashi, Hideaki, Ueno, Makoto, Kobayashi, Satoshi, Morimoto, Manabu, Okusaka, Takuji, Ueno, Hideki, Morizane, Chigusa, Okano, Naohiro, Nagashima, Fumio, Furuse, Junji
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Springer US 2018
विषय:
Phase I Studies
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6538570/
https://ncbi.nlm.nih.gov/pubmed/30511200
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-018-0697-3
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन